Cat. No. 3227
Alternative Name: Kallidin
Biological ActivityEndogenous bradykinin receptor agonist that displays some selectivity for the B2 receptor (Ki values are 2.54 and 0.63 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. Twice as potent as bradykinin (Cat No. 3004) in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Leeb-Lundberg et al (2005) International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol.Rev. 57 27. PMID: 15734727.
Regoli et al (2001) Classification of kinin receptors. Biol.Chem. 382 31. PMID: 11258668.
Regoli and Barabe (1980) Pharmacology of bradykinin and related kinins. Pharmacol.Rev. 32 1. PMID: 7015371.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Lys-Bradykinin from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Lys-Bradykinin, supplier, Potent, bradykinin, receptor, agonists, B2, B1, Receptors, Tocris Bioscience, Bradykinin Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.